SCHEMBL2663880

SCHEMBL2663880

Cc1ccc(CN2C(=O)c3cccc(F)c3C2CCC(=O)Nc2ccc(C)cn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.49
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
KMT2A Q03164 4/20 0.41
MEN1 O00255 2/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643961 0.96 HTT (0.46) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL15925794 0.93 KMT2A (0.48) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL15925793 0.92 HTT (0.42) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL15925790 0.92 HTT (0.42) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL15925792 0.91 HTT (0.41) HTTRAB9ASMN1; SMN2NPC1CDK5
SCHEMBL15925791 0.90 KDM4E (0.48) HTTSMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL2643618 0.89 MAPT (0.40) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL2644875 0.87 SMN1; SMN2 (0.47) HTTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL2643760 0.87 WNT3A (0.42) SMN1; SMN2NPC1CDK5CDK5R1KDM4E
SCHEMBL2644105 0.86 MAPT (0.46) HTTRAB9ANPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase GCK, GCKR, GPR119 HTT 3123/4885RAB9A 3226/4885SMN1; SMN2 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.